



## Clinical Program GWG Recommendations

Gil Sambrano  
Vice President, Portfolio Development and Review  
California Institute for Regenerative Medicine


**TRANSFORMING**

*medicine  
lives  
futures*

April 26, 2018



# Clinical Stage Programs



# Scoring System for Clinical Applications

- **Score of “1”**

*Exceptional merit and warrants funding.*

- **Score of “2”**

*Needs improvement and does not warrant funding at this time but could be resubmitted to address areas for improvement.*

- **Score of “3”**

*Sufficiently flawed that it does not warrant funding and the same project should not be resubmitted **for at least 6 months.***

Applications are scored by all scientific members of the GWG with no conflict.

# CLIN2-10830: Phase 1 Clinical Trial of Therapy for Artemis-SCID

## Project Summary

<b>Therapy</b>	Gene-corrected blood stem cell transplant
<b>Indication</b>	Children with severe combined immunodeficiency (SCID) due to Artemis gene defect
<b>Goal</b>	Complete a phase 1 clinical trial to assess safety and feasibility of the therapy
<b>Funds Requested</b>	\$12,000,000 (\$0 Co-funding)

Maximum funds allowable for this category: \$12,000,000

# CLIN2-10830: Phase 1 Clinical Trial of Therapy for Artemis-SCID

**GWG Recommendation:** Exceptional merit and warrants funding

Score	GWG Votes
1	15
2	0
3	0

**CIRM Team Recommendation:** Fund (concur with GWG recommendation)

**Award Amount:** \$12,000,000\*

\*Final award shall not exceed this amount and may be reduced contingent on CIRM's final assessment of allowable costs and activities.

# CLIN2-10846: Phase 1 Clinical Trial of a (CAR) T Cell Therapy for B Cell Cancers

## Project Summary

<b>Therapy</b>	T cells genetically engineered to target CD19 and/or CD22 on cancer B cells
<b>Indication</b>	Patients with relapsed and refractory B cell cancers
<b>Goal</b>	Complete phase 1 trial to assess safety and feasibility of the therapy
<b>Funds Requested</b>	\$11,976,906 (\$2,283,796 Co-funding)

Maximum funds allowable for this category: \$12,000,000

# CLIN2-10846: Phase 1 Clinical Trial of a (CAR) T Cell Therapy for B Cell Cancers

**GWG Recommendation:** Exceptional merit and warrants funding

Score	GWG Votes
1	13
2	1
3	0

**CIRM Team Recommendation:** Fund (concur with GWG recommendation)

**Award Amount:** \$11,976,906\*

\*Final award shall not exceed this amount and may be reduced contingent on CIRM's final assessment of allowable costs and activities.

# CLIN2-11031: Phase 1/2 Clinical Trial of a Therapy for Beta-Thalassemia

## Project Summary

<b>Therapy</b>	Gene-corrected, autologous blood stem cell transplant
<b>Indication</b>	Patients with transfusion-dependent beta-thalassemia
<b>Goal</b>	Complete phase 1/2 trial to assess safety, activity, and efficacy of the therapy
<b>Funds Requested</b>	\$8,000,000 (\$14,993,120 Co-funding)

Maximum funds allowable for this category: \$8,000,000

# CLIN2-11031: Phase 1/2 Clinical Trial of a Therapy for Beta-Thalassemia

**GWG Recommendation:** Exceptional merit and warrants funding

Score	GWG Votes
1	12
2	0
3	0

**CIRM Team Recommendation:** Fund (concur with GWG recommendation)

**Award Amount:** \$8,000,000\*

\*Final award shall not exceed this amount and may be reduced contingent on CIRM's final assessment of allowable costs and activities.